Investment Opportunities in the Pharmaceutical Industry from the Perspective of Drug Terminal Markets | 2021 CPEO Conference

Since 2015, the size of China’s pharmaceutical end-user market has shifted from a phase of rapid growth (2010–2014, with a compound annual growth rate [CAGR] of 17%) to one of moderate-to-slow growth (2015–2021E, with a CAGR of 5%), yet significant divergence has emerged across its subsectors. Beneath the surface currents, the biopharmaceutical industry is in fact undergoing structural adjustment. What investment opportunities lie within this transformation?

• Pharmaceuticals Sector:What Does the R&D Competitive Landscape Look Like for Innovative Drug Companies? Are Modified New Drugs a Last Resort or a Way to Break Through? How Can Generic Drug Companies Transform Under Volume-Based Procurement?

• Vaccine Sector:Spurred by the COVID-19 pandemic, the vaccine sector has seen explosive growth. How long will this momentum last, and which products will remain the mainstay?

• Traditional Chinese Medicine Sector:In recent years, market growth has been sluggish, with valuations remaining persistently low. How can the gap between policy and market dynamics be bridged, and which companies have achieved counter-trend growth amid these challenges?

• Chain Pharmacy Sector:From Outbound Capital Inflows to Five-Year Low Valuations: How Will Internet Healthcare and Chain Pharmacies Compete and Collaborate in the Future? Will Chain Pharmacies Face Opportunities or Challenges?

Zhongkang’s Insight Report, “Investment Opportunities in the Pharmaceutical Industry from the Perspective of the Terminal Drug Market,” will comprehensively analyze development trends in the pharmaceutical industry and deeply explore investment opportunities, leveraging Zhongkang’s terminal drug market data.